UZ Brussel HRMC Registry of Brugada Syndrome
HRMCBrS
UZ Brussel Heart Rhythm Management Center Monocentric Registry of Brugada Syndrome
1 other identifier
observational
2,000
1 country
1
Brief Summary
The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome at UZ Brussel hospital (UZB).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1992
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1992
CompletedFirst Submitted
Initial submission to the registry
February 23, 2022
CompletedFirst Posted
Study publicly available on registry
March 17, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2032
March 17, 2022
March 1, 2022
40 years
February 23, 2022
March 12, 2022
Conditions
Outcome Measures
Primary Outcomes (5)
Ventricular arrhythmias
Composite of: sudden cardiac death, aborted sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, ICD appropriate therapy
through study completion, an average of 10 year
Atrial fibrillation
Atrial fibrillation occurrence
through study completion, an average of 10 year
Death for any cause
Death for any cause
through study completion, an average of 10 year
Cardiovascular death
Death for cardiovascular cause
through study completion, an average of 10 year
Genetic mutations
Genetic mutations (pathogenic and variant of unknown significance) associated with Brugada syndrome. Wide gene panel with next generation sequencing will be used: Roche SeqCap® EZ Human Exome Probes v3.0 for BrS.
Baseline
Interventions
Eligibility Criteria
Brugada syndrome patients diagnosed following current guidelines: (Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-2867.) Both Brugada spontaneous type 1 and ajmaline induced will be included.
You may qualify if:
- Brugada syndrome diagnosis
You may not qualify if:
- Other diagnosis different from Brugada syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UZ Brussel Heart Rhythm Management Center
Brussels, 1090, Belgium
Biospecimen
Blood sample for DNA analysis
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 30 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of Heart Rhythm Management Center
Study Record Dates
First Submitted
February 23, 2022
First Posted
March 17, 2022
Study Start
January 1, 1992
Primary Completion (Estimated)
January 1, 2032
Study Completion (Estimated)
January 1, 2032
Last Updated
March 17, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share
No IPD sharing